Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo Bioworks Holdings, Inc. filed a Form 8-K reporting the results of its 2022 annual meeting of shareholders held on June 10, 2022. The filing concerns corporate governance matters and does not report quarterly or annual operating results.
Key financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
A total of 859,915,040 shares of Class A common stock and 351,470,842 shares of Class B common stock were present or represented by proxy. This represented approximately 81.47% of the shares entitled to vote as a single class and approximately 89.15% of Class B shares entitled to vote separately.
Meeting results and material changes
- All eight director nominees were elected to serve until the next annual meeting or until their successors are elected and qualified.
- Jason Kelly and Reshma Shetty were elected by Class B shareholders voting separately.
- Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar, and Harry E. Sloan were elected by Class A and Class B shareholders voting together.
- Class A shares carry one vote per share, while Class B shares carry ten votes per share.
- Shareholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
| Proposal | Votes for | Votes against | Abstentions | Broker non-votes |
|---|---|---|---|---|
| Auditor ratification | 4,365,263,156 | 5,152,427 | 4,207,877 | 0 |
Guidance, outlook, risks, and unusual items
The filing provides no financial guidance, business outlook, risk-factor updates, contingencies, or unusual accounting items. The principal governance consideration is the company’s dual-class voting structure, under which Class B shareholders have ten votes per share.
Important facts for investors to verify
- Confirm the continuing composition of the eight-member board following the annual meeting.
- Consider the effect of the ten-to-one Class B voting rights on shareholder influence and corporate control.
- Verify Ernst & Young LLP’s appointment for the fiscal year ending December 31, 2022.
- Review the company’s periodic financial filings separately because this 8-K contains no financial performance data.